Project Details
Description
PROJECT SUMMARY
Ischemic heart disease, such as unstable coronary angina or myocardial infarction, often leads to systolic heart
failure due to the loss of contractile cardiomyocytes. Engineered heart tissue mediated transplantation of stem
cell derived cardiomyocytes holds the promise to regenerate the myocardium and improve cardiac function
post myocardial infarction in preclinical animal models. Despite these encouraging results, several critical
barriers limit the clinical application of engineered heart tissue-based therapy. For example, the poor perfusion
in the infarct area compromises the survival of transplanted cardiomyocytes. In addition, the procedure of
transplantation of engineered heart tissue typically requires open chest surgery which is a significant challenge
to the patients with severe heart failure. Data from our previous studies showed that promoting cell cycle and
proliferation in human induced pluripotent stem cells (hiPSC-CMs) constitutes a viable approach to enhance
engraftment and restore function in ischemic heart disease. We also generated a new type of nanoparticles
that enable myocardial protection via increased vasculogenesis in the ischemic heart. Furthermore, we
established an injectable and shape-recoverable tissue with GelMA-coated nanofiber scaffolds. In this project,
we aimed to develop novel approaches to enhance the engraftment of implanted hiPSC-CMs via integrating
nanomaterials, cell- and tissue-engineering technologies. Specifically, we will 1) develop a novel engineered
heart tissue which leverages the capacity of nanomaterials to release pro-vasculogenic molecules and promote
revascularization in these engineered heart tissues and in the infarct heart; 2) take the advantage of our
recently established protocol to induce the proliferation of survival cardiomyocytes inside the engineered heart
tissues; and 3) study if delivery of these novel engineered heart tissues to animals with acute or chronic
myocardial infarction leads to robust myocardial regeneration and repair.
Status | Active |
---|---|
Effective start/end date | 1/1/23 → 11/30/24 |
Funding
- National Heart, Lung, and Blood Institute: $652,089.00
- National Heart, Lung, and Blood Institute: $762,200.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.